Previous sessionNext session Enhancing hepatitis C treatment outcomes among people who use drugs Evidence to guide future practice and policyInsights zone 1 (I1) In programme Thursday, 24 October, 2019 - 13:20 to 14:50 View presentations Chair MatheïCatharina KU LeuvenBelgium DunlopAdrian Hunter New England Local Health DistrictAustralia Tracks The future of hepatitis C among people who inject drugs: new frontiers for policy, practice and science Keywords Clinical toolsInfectious diseasesVulnerable groupsTreatment: medical/pharmacologicalOpiatesOverdoseProgramme evaluation Presentations Plenary session Poster session Big debate Structured session Workshop Oral presentation session Short communication session Poster guided tour 13:30 Oral presentation HepCATT (Hepatitis C Assessment to Treatment Trial) in primary care: a cluster RCT of whether a complex intervention based on risk prediction algorithm tool and education can increase testing and diagnosis of HCV in primary care 13:30 to 13:45 Insights zone 1 (I1) Matthew Hickman 13:45 Oral presentation Real-life effectiveness of direct-acting antiviral treatment among chronic hepatitis C infected opioid substituted patients in Germany 13:45 to 14:00 Insights zone 1 (I1) Bernd Schulte 14:00 Oral presentation Hepatitis C Virus (HCV) elimination and the opioid crisis: joint problems, joint solution – results of a pilot programme 14:00 to 14:15 Insights zone 1 (I1) Brian Conway 14:15 Oral presentation Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST 14:15 to 14:30 Insights zone 1 (I1) Tina McHugh 14:30 Oral presentation The cost-effectiveness of an HCV outreach intervention for at risk populations in London 14:30 to 14:45 Insights zone 1 (I1) Zoe Ward Oral presentation Reduction in the population prevalence of chronic HCV among people who inject drugs associated with major scale-up of direct-acting antiviral therapy in community drug services: real world data 14:30 to 14:45 Insights zone 1 (I1) Norah Palmateer
